Involving A Micro-organism Or Cell Membrane Bound Antigen Or Cell Membrane Bound Receptor Or Cell Membrane Bound Antibody Or Microbial Lysate Patents (Class 435/7.2)
  • Patent number: 10688127
    Abstract: Methods for use of structures based on graphene-related materials are disclosed. These structures can be utilized for manipulating the cell transmembrane potential in various biomedical applications.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: June 23, 2020
    Inventor: Elena Molokanova
  • Patent number: 10639371
    Abstract: The present invention provides a bioconjugate. The bioconjugate comprises a first molecule comprising an elastin-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule. The bioconjugate is self-assembled into particles, which are disassembled when the temperature is increased. Also provided is a method for delivering a bioconjugate to a target matrix, comprising (a) introducing a bioconjugate self-assembled into particles to a target matrix, wherein the bioconjugate comprises a first molecule comprising an elastin-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule, and (b) increasing the temperature of the target matrix to disassemble the particles at the target matrix.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 5, 2020
    Assignee: University of Delaware
    Inventors: Kristi Kiick, Tianzhi Luo
  • Patent number: 10632175
    Abstract: The present invention is related to methods and compositions effective in regulating glycemic control in subject individuals in need of the regulation of glycemic control. Said individuals may have diabetes or be prediabetic condition receive therapeutically effective amounts of identified secreted proteins in an amount suitable for modulating glycemic control and to thereby treat or prevent diabetes in said subject.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: April 28, 2020
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Laurie J. Goodyear, Kristin I. Stanford
  • Patent number: 10627408
    Abstract: Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of ?-gliadin 33-mer, ?-gliadin-17-mer, ?-gliadin-15-mer, ?-gliadin-17-mer, and glutenin 21-mer.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 21, 2020
    Assignee: Cyrex Laboratories, LLC
    Inventor: Aristo Vojdani
  • Patent number: 10611834
    Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: April 7, 2020
    Assignee: Osaka University
    Inventors: Toshihide Yamashita, Yasufumi Hayano, Moe Yamada
  • Patent number: 10613083
    Abstract: A biosensor system for the detection of target analytes that includes a living biological cell of a predetermined type; a signal-generating reporter associated with the living biological cell; a signal transduction pathway or other activator mechanism or means associated with the signal-generating reporter; a universal detector element associated with the activator mechanism; and an analyte binding element associated with the universal detector element, wherein the analyte binding element is specific to both the universal detector element and a target analyte.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 7, 2020
    Assignee: Fundamental Solutions Corporation
    Inventors: Thomas J. Zupancic, Joseph D. Kittle, Lingchun Zeng, Srikanth Vedamoorthy, Richard S. Brody, Marvin R. Williams
  • Patent number: 10597697
    Abstract: The invention discloses a method for determining a nucleotide sequence of a nucleic acid segment present in a biological sample, comprising the steps of: a) generating a fluorescent image of the sample by a protocol comprising immunofluorescence detection of at least five different target proteins in the sample; b) selecting a region of interest of the sample by comparing the image to a predetermined criterion; c) removing a subsample from the region of interest, and; d) determining a nucleotide sequence of a nucleic acid segment present in the subsample.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: March 24, 2020
    Assignee: GE Healthcare Bio-Sciences Corp.
    Inventors: John Richard Nelson, Qingyan Au, Wei Gao, Ryan Charles Heller, Nicholas Hoe, Nam Tran, Nichole Lea Wood
  • Patent number: 10591364
    Abstract: The present invention relates to the use of one or more amplicons as temperature calibrators. In some embodiments, the calibrators may be used to calibrate the temperature of a microfluidic channel in which amplification and/or melt analysis is performed. In some embodiments, the amplicons may be genomic, ultra conserved elements and/or synthetic. The amplicon(s) may have a known or expected melt temperature(s). The calibrators may be added to primers of study or may follow or lead the primers of study in the channel. The amplicon(s) may be amplified and melted, and the temperature(s) at which the amplicon(s) melted may be determined. The measured temperature(s) may be compared to the known temperature(s) at which the amplicon(s) was expected to melt. The difference(s) between the measured and expected temperatures may be used to calibrate/adjust one or more temperature control elements used to control and/or detect the temperature of the channel.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: March 17, 2020
    Assignee: Canon U.S.A., Inc.
    Inventors: Fernando DeCastro, Renee Howell, Sami Kanderian, Johnathan S. Coursey, Kenton C. Hasson, Scott Sundberg
  • Patent number: 10543243
    Abstract: The invention relates to a soybean seed extract, method for producing the same and uses of the extract of soybean seeds in promoting wound healing, promoting neuron cell proliferation and/or treating brain diseases and/or neurodegenerative diseases, treating breast cancer, reducing side effects of interfering with DNA and/or RNA replication drugs and/or enhancing pharmaceutical effects of interfering with DNA and/or RNA replication drugs.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: January 28, 2020
    Assignee: CHARSIRE BIOTECHNOLOGY CORP.
    Inventor: Chu I-Hung
  • Patent number: 10544472
    Abstract: A protein reporter system comprising at least one reporter including a response element responsive to the binding of a transcription factor, a secreted enzyme backbone and a recognition region for specific binding of an antibody. Multiplexed assays for binding, assaying and quantifying the activity of transcription factors are also described, in which the assays use protein reporters in sets, libraries or other groupings, as necessary to achieve desired quantification.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 28, 2020
    Assignee: ATTAGENE, INC.
    Inventors: Sergei S. Makarov, Ming Zheng
  • Patent number: 10539540
    Abstract: A minimum peak is determined from analysis results, a correction wavelength at which an S/N ratio of the minimum peak is greatest is determined, and the determined correction wavelength is used to execute correction of the minimum peak. A plurality of detector output value correction method are registered in a processor, correction method is selected from default correction method or from among a plurality of preset correction methods according to an object to perform correction.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 21, 2020
    Assignee: HITACHI HIGH-TECH SCIENCE CORPORATION
    Inventors: Shuhei Yamamura, Daisuke Akieda, Ayumi Nakaogami, Katsutoshi Shimizu
  • Patent number: 10539570
    Abstract: In various implementations, a noninvasive, food sensitivity test may be utilized to identify one or more food sensitivities. A fecal sample may be obtained. The food sensitivity test may be performed on the obtained fecal sample. One or more food sensitivities may be identified based on the food sensitivity test.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: January 21, 2020
    Inventor: Kenneth Davin Fine
  • Patent number: 10526412
    Abstract: An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 7, 2020
    Assignees: UNIVERSITE GRENOBLE ALPES, UNIVERSITE DE LAUSANNE
    Inventors: Bertrand Huard, Pascal Schneider
  • Patent number: 10501531
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 10492717
    Abstract: A method includes receiving multiple compound muscle action potential values (CMAPs), wherein each CMAP is an onset latency, a peak latency, a conduction velocity, or a response amplitude measured from a baseline; for each of the CMAPs and for each of a number parameters calculated from the CMAPs, determining a corresponding demyelinating boundary value using a normal value from a preselected population; determining whether each of the CMAPs and each of the parameters exceeds the corresponding demyelinating boundary value; determining one or more demyelinated nerve pathways based on which of the CMAPs and the parameters exceeds the corresponding demyelinating boundary value; indicating on a display which of the CMAPs and the parameters exceed the corresponding demyelinating boundary value; and displaying, in pictorial form, an anatomical diagram indicating the demyelinated nerve pathways.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: December 3, 2019
    Assignee: The Research Foundation of State University of New York
    Inventors: Paul Jacob Maccabee, Lawrence Philip Eberle
  • Patent number: 10487114
    Abstract: The present invention features methods and compositions for the generation of conformation-specific antibodies.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: November 26, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Patent number: 10465164
    Abstract: The method provides a hyaluronic-acid binding based technique to separate functionally competent and mature sperm. The method for extracting viable sperms from a semen sample comprises incubating functionalized HA with functionalized paramagnetic beads to obtain a plurality of HA coated paramagnetic beads. The method further comprises incubating the plurality of HA coated paramagnetic beads with the semen sample to obtain a first population and a second population of sperm. The first population comprises sperm bound to the plurality of HA coated paramagnetic beads and the second population comprises sperms not bound to the plurality of HA coated paramagnetic beads. The method comprises magnetically separating the first population from the second population and separating sperms from the plurality of HA coated paramagnetic beads in the separated first population to obtain the viable sperms.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 5, 2019
    Assignees: ACHIRA LABS PVT. LTD., VASAN SATYA SRINI
    Inventors: Dhananjay Dendukuri, Satish Kalme, Vijetha Nagendra Prakash, Gokul R Prasath, Vasan Satya Srini
  • Patent number: 10449206
    Abstract: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 22, 2019
    Assignee: Natreon, Inc.
    Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
  • Patent number: 10416162
    Abstract: In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 17, 2019
    Assignee: Monogram Biosciences, Inc.
    Inventors: Weidong Huang, Jeff Sperinde, Michael Bates, Colombe Chappey, John William Winslow
  • Patent number: 10371696
    Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: August 6, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Rakesh Sindhi
  • Patent number: 10365283
    Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 30, 2019
    Assignee: Daiichi Sankyo Europe GmbH
    Inventors: Mike Rothe, Martin Treder
  • Patent number: 10351823
    Abstract: Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 16, 2019
    Assignee: Q THERAPEUTICS, INC.
    Inventors: Robert Sandrock, James T. Campanelli, Deborah A. Eppstein
  • Patent number: 10336806
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 2, 2019
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 10324098
    Abstract: Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: June 18, 2019
    Assignee: SENOMYX, INC.
    Inventor: Jon Elliot Adler
  • Patent number: 10214584
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 26, 2019
    Assignee: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki Satofuka, Kensuke Ohse, Shigeki Mukobata, Hirotada Akiyama, Masaya Ohtsu, Yoko Okabe, Yasufumi Murakami
  • Patent number: 10160978
    Abstract: The invention relates to mammalian cells comprising at least one prokaryotic two-component signaling (TCS) pathway comprised of an activator protein A, a response regulator (RR) protein B activated by said protein A, such activation leading to an activated RR protein B, and an output gene C operably linked to a promoter. Transcription from said promoter is activated by activated RR protein B, and the expression of output gene C defines at least a first state (0, no transcription) and a second state (1, detectable transcription). The invention further relates to logic gates designed from such cells, and methods for integrating a plurality of output signals based on the cells and logic gates of the invention.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: December 25, 2018
    Assignee: ETH ZURICH
    Inventors: Yaakov Benenson, Jonathan Hansen, Krishna Kumar Swaminathan
  • Patent number: 10145794
    Abstract: A cell information obtaining method comprises causing a plurality of fluorescent substances having different fluorescence wavelengths from each other to be bound to a test substance contained in a cell, applying light to the cell to cause fluorescences having different wavelengths and intensities to be generated from the plurality of fluorescent substances, and obtaining a first fluorescence information and a second fluorescence information on the basis of the generated fluorescences.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: December 4, 2018
    Assignee: SYSMEX CORPORATION
    Inventor: Keiko Yoshikawa
  • Patent number: 10137150
    Abstract: Structures based on graphene-related materials, methods for their preparation, and methods for their use are disclosed. These structures can be utilized for manipulating the cell transmembrane potential in various biomedical applications.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: November 27, 2018
    Inventor: Elena Molokanova
  • Patent number: 10139404
    Abstract: The present invention relates to the use of a control marker for implementing analysis methods on spots, in particular in the context of multiplex analyses. The present invention thus relates to solid supports containing said control marker, their preparation method and their use in analysis methods. The present invention makes it possible to verify the presence, location and/or integrity of the spots at the end of the analysis method, and thus to secure the obtained results while guaranteeing that the yielded result indeed results from a present, intact and localized spot.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: November 27, 2018
    Assignee: BIO-RAD EUROPE GMBH
    Inventors: Agnes Roseline Claude Pouzet, Vincent Doury, Laurent Emmanuel Fournier, Christophe Rene Roger Vedrine
  • Patent number: 10130593
    Abstract: This disclosure concerns the discovery of the use of fenoterol analogs for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analog to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: November 20, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Irving William Wainer, Michel Bernier, Rajib Kumar Paul
  • Patent number: 10106595
    Abstract: The present invention relates to fusion proteins for the expression of G-protein coupled receptor proteins (GPCR) with the fusion partners, as inserted fragments, from mammalian cells. The fusion partners are from a fragment of APJ protein (“the APJ protein fragment”) or a fragment with homology of more than 90% similarity to the APJ protein fragment; or a fragment of RGS16 protein (the “RGS16 protein fragment”) or a fragment with homology of more than 90% similarity to the RGS16 protein fragment; or the fragment of DNJ protein (the “DNJ protein fragment”) or a fragment with homology of more than 90% similarity to DNJ protein fragment. The fusion expression of GPCR with the above mentioned fusion partners can improve the protein yield and stability when purified from cells. Therefore, these fusion protein partners can be widely used for the study of GPCR proteins.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 23, 2018
    Assignee: VIVA BIOTECH (SHANGHAI) LTD.
    Inventors: Jianhua Cai, Jian Shen, Fan Jiang, Na Li, Wentao Wei, Xiuhong Zeng, Xiaoyan Su, Min Han, Delin Ren, Chen Mao
  • Patent number: 10100128
    Abstract: Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: October 16, 2018
    Assignee: AROCELL AB
    Inventor: Staffan Eriksson
  • Patent number: 10087208
    Abstract: Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 2, 2018
    Assignee: AM CHEMICALS LLC
    Inventors: Andrei Pavel Guzaev, Vladimir Y. Vvedenskiy
  • Patent number: 10078087
    Abstract: This invention relates to electrophysiological assays that measure sodium conductance activity of a delta human epithelial sodium channel (ENaC) in the presence and absence of delta hENaC enhancers. Also, the invention generally relates to assays for identifying compounds that enhance the activity of delta hENaC, especially in an oocyte expression system. These compounds have potential application in modulating (enhancing) salty taste perception.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: September 18, 2018
    Assignee: SENOMYX, INC.
    Inventors: Bryan Moyer, Min Lu, Fernando Echeverri, Hong Chang
  • Patent number: 9994605
    Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: June 12, 2018
    Assignee: UNIVERSITAET BASEL
    Inventors: Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
  • Patent number: 9982260
    Abstract: This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a compound such as, for example, Perphenazine, Flupentixol DiHCl, Zuclopenthixol or Corynanthine HCl, or a compound which shares a similar 2-D structure and activity level with one of these compounds, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer of the compound, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: May 29, 2018
    Assignee: The Regents of The University of California
    Inventors: Genevieve C. Kendall, Stanley F. Nelson, M. Carrie Miceli
  • Patent number: 9970848
    Abstract: The invention relates to providing a method for more conveniently evaluating stratum corneum condition. A stratum corneum sheet is contacted with a solution of a water-soluble dye, and the staining intensity or fluorescence intensity is measured to allow convenient evaluation of the stratum corneum condition. There is further provided a method for evaluating the ameliorating effect of a cosmetic or cosmetic treatment on the stratum corneum, by implementing the method for evaluating stratum corneum condition using a water-soluble dye according to the invention.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: May 15, 2018
    Assignee: Shiseido Company, Ltd.
    Inventors: Eiichiro Yagi, Ichiro Iwai
  • Patent number: 9968935
    Abstract: The present invention relates to the field of molecular diagnostics. In particular, the present invention provided improved substrates and methods of using liquid crystals and other biophotonically based assays for quantitating the amount of an analyte in a sample. The present invention also provides materials and methods for detecting non-specific binding of an analyte to a substrate by using a liquid crystal or other biophotonically based assay formats.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: May 15, 2018
    Assignee: Platypus Technologies, LLC
    Inventors: Nicholas Abbott, Christopher Murphy, Barbara Israel, Josh Sotos, Doug Hansmann, Renee Herber, Joseph Burkholder, Keren Hulkower, Michael Bonds
  • Patent number: 9952202
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic disease. The invention further provides in vitro methods for inhibition of fibroblast migration and differentiation.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 24, 2018
    Assignee: GALAPAGOS NV
    Inventors: Richard Antonius Jozef Janssen, Annemarie Nicolete Lekkerkerker, Jamil Aarbiou, Krista Ouwehand
  • Patent number: 9939587
    Abstract: An on-chip optical filter having Fabri-Perot resonators and a spectrometer may include a first sub-wavelength grating (SWG) reflecting layer and a second SWG reflecting layer facing each other. A plurality of Fabri-Perot resonators are formed by the first SWG reflecting layer and the second SWG reflecting layer facing each other. Each of the Fabri-Perot resonators may transmit light corresponding to a resonance wavelength of the Fabri-Perot resonator. The resonance wavelengths of the Fabri-Perot resonators may be determined according to duty cycles of grating patterns.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 10, 2018
    Assignees: SAMSUNG ELECTRONICS CO., LTD., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Seunghoon Han, Yu Horie, Andrei Faraon, Amir Arbabi
  • Patent number: 9925537
    Abstract: A microfluidic device is configured to analyze a sample of biological material. The microfluidic device includes a fluid guide structure constructed in order to divide a sample introduced into the microfluidic device into a plurality of subquantities. The microfluidic device further includes a plurality of reaction chambers each of which is fluidically connected to the fluid guide structure. Each of the reaction chambers has a filter configured to filter out target cells from the sample, and each of the reaction chambers is constructed to receive a sample subquantity. In each of the reaction chambers, a result of a reaction between a target-cell-specific active substance that is different for each of the reaction chambers and the target cells of the sample subquantity that is taken up is acquirable.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Robert Bosch GmbH
    Inventor: Jochen Hoffmann
  • Patent number: 9903867
    Abstract: The present invention provides assays and methods for predicting the survival of a subject having colorectal cancer (CRC), thereby determining whether the subject will have a good prognosis or poor prognosis. The present invention also provides assays and methods for predicting therapeutic efficacy and/or response to anti-cancer therapeutics in a subject having CRC, thereby selecting a therapeutic regimen to which the subject is likely to be responsive.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 27, 2018
    Assignee: Nestec S.A.
    Inventors: Phillip Kim, Anjali Jain, Sharat Singh
  • Patent number: 9897848
    Abstract: The invention provides a manufacturing method of color resist layer to manufacture the color resist layer by micro transfer printing (MTP), comprising forming a color resist thin film on a first substrate, using a MTP transfer stamp to adsorb a part of the color resist thin film to the plurality of protrusions of the MTP transfer stamp, and transferring the color resist thin film adsorbed by the plurality of protrusions of the MTP transfer stamp to the second substrate to form the color resist layer on the second substrate. The method uses the protrusions of the MTP transfer stamp to form the pattern to control the pattern of the color resist layer instead of exposure and development. No color resist material is wasted, the cost is reduced and the process is simple and widely applicable.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 20, 2018
    Assignee: SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD.
    Inventor: Lixuan Chen
  • Patent number: 9880152
    Abstract: Described herein are compositions, methods and/or kits for determining the likelihood of a pregnant subject delivering at term, or developing a disorder associated with pregnancy. These compositions, methods and/or kits feature the measurement of the chemotactic activity of peripheral leukocytes, the measurement of ccl2 mRNA expression or the measurement of Fp or Otr protein expression.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 30, 2018
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Nardhy Gomez-Lopez, David Olson
  • Patent number: 9862924
    Abstract: Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 9, 2018
    Assignee: Wake Forest University Health Sciences
    Inventor: Khalil Bitar
  • Patent number: 9856254
    Abstract: Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: January 2, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Kyle J. Lindstrom, Bryon A. Merrill, Chad A. Haraldson, Michael J. Rice, Tushar A. Kshirsagar, Philip D. Heppner, Joshua R. Wurst, Shri Niwas, Sarah J. Slania
  • Patent number: 9856535
    Abstract: A system and method for isolating cells, comprising: a substrate having a broad surface; an array comprising a set of wells defined at the broad surface of the substrate, each well including: a base surface, an open surface directly opposing the base surface, defined at the broad surface of the substrate, and configured to receive one of a single cell and a single cluster of cells from a direction perpendicular to the broad surface of the substrate, and a set of channels that fluidly couple each well to at least one adjacent well; wherein the set of wells includes an interior subset and an exterior subset fluidly coupled to and surrounding the interior subset by way of the set of channels; and a fluid delivery module surrounding the array and fluidly coupled to each well in the set of wells.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: January 2, 2018
    Assignee: DeNovo Sciences, Inc.
    Inventors: Kalyan Handique, Priyadarshini Gogoi, Yi Zhou, Saedeh Sepehri, Christopher Siemer
  • Patent number: 9828625
    Abstract: Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: November 28, 2017
    Assignee: Phage Diagnostics, Inc.
    Inventors: Michael Sandor Koeris, Julie Thomason, Michael Cappillino, Robert Patrick Shivers, Daniel Robert Brownell, Jayson L. Bowers, Timothy Kuan Ta Lu, Edyta Krzymanska-Olejnik
  • Patent number: 9770478
    Abstract: The invention relates to a novel use of the Chinese herb Glycyrrhiza inflata in treatment of neurodegenerative disorders. Particularly, the invention relates to the use of ammonium glycyrrhizinate and licochalcone A in targeting polyQ-mediated spinocerebellar ataxia.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: September 26, 2017
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Guey-Jen Lee-Chen, Chiung-Mei Chen
  • Patent number: 9771554
    Abstract: A device for assembling aggregations of adherent cells includes a gripper moveable within an assembly vessel that fixes aggregations of adherent cells at a membrane of the gripper and, by movement of the gripper, assembles aggregations of cells on a separate membrane within the vessel, thereby creating a three-dimensional assembly of aggregations of cells that fuse and can be employed in surgical procedures as a unitary tissue of adherent cells. The aggregations of cells, as assembled, can assume three-dimensional configurations distinct from any one of the component aggregations of cells assembled.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: September 26, 2017
    Assignees: Brown University, Rhode Island Hospital
    Inventors: Jeffrey R. Morgan, Andrew Blakely, John Murphy, Anubhav Tripathi, William Patterson